Major findings and recent advances in virus-like particle (VLP)-based vaccines.

Mohsen, Mona; Zha, Lisha; Cabral-Miranda, Gustavo; Bachmann, Martin (2017). Major findings and recent advances in virus-like particle (VLP)-based vaccines. Seminars in immunology, 34, pp. 123-132. W.B. Saunders 10.1016/j.smim.2017.08.014

Text 1-s2.0-S1044532317300386-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (849kB)

Virus-like particles (VLPs) have made giant strides in the field of vaccinology over the last three decades. VLPs constitute versatile tools in vaccine development due to their favourable immunological characteristics such as their size, repetitive surface geometry, ability to induce both innate and adaptive immune responses as well as being safe templates with favourable economics. Several VLP-based vaccines are commercially available including vaccines against Human Papilloma Virus (HPV) such as Cervarix®, Gardasil® & Gardasil9® and Hepatitis B Virus (HBV) including the 3rd generation Sci-B-Vac™. In addition, the first licensed malaria-VLP-based vaccine Mosquirix™ has been recently approved by the European regulators. Several other VLP-based vaccines are currently undergoing preclinical and clinical development. This review summarizes some of the major findings and recent advances in VLP-based vaccine development and technologies and outlines general principles that may be harnessed for induction of targeted immune responses.

Interest & Impact

Downloads

5 since deposited on 19 Mar 2018
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item